Biogen Inc. (BIIB)
Company Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.
In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.
Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development.
The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc.
Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| IPO Date | Sep 17, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,605 |
| CEO | Christopher A. Viehbacher |
Contact Details
Address: 225 Binney Street Cambridge, Massachusetts United States | |
| Website | https://www.biogen.com |
Stock Details
| Ticker Symbol | BIIB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875045 |
| CUSIP Number | 09062X103 |
| ISIN Number | US09062X1037 |
| Employer ID | 33-0112644 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Viehbacher | President, Chief Executive Officer & Director |
| Robin C. Kramer | Executive Vice President & Chief Financial Officer |
| Susan H. Alexander Esq. | Executive Vice President & Chief Legal Officer |
| Adam Keeney Ph.D. | Executive Vice President & Head of Corporate Development |
| Dr. Ginger Gregory Ph.D. | Executive Vice President & Chief Human Resources Officer |
| Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs |
| Nicole Murphy | Executive Vice President and Head of Pharmaceutical Operations & Technology |
| Rachid Izzar | Executive Vice President and Head of Global Product Strategy & Commercialization |
| Sean Godbout | Chief Accounting Officer & Global Corporate Controller |
| Tim Power M.B.A., Ph.D. | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 10, 2025 | 4 | Filing |
| Mar 10, 2025 | 3 | Filing |
| Mar 07, 2025 | 144 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |
| Feb 12, 2025 | 4 | Filing |